Jeff Johnson
Stock Analyst at Baird
(4.56)
# 205
Out of 5,182 analysts
154
Total ratings
54.29%
Success rate
27.43%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Upgrades: Outperform | $78 → $100 | $76.12 | +31.37% | 11 | Feb 23, 2026 | |
| BBNX Beta Bionics | Maintains: Neutral | $28 → $14 | $10.08 | +38.89% | 3 | Feb 18, 2026 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $18 → $30 | $18.63 | +61.03% | 17 | Dec 16, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $117 → $100 | $82.80 | +20.77% | 15 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $85 → $98 | $63.09 | +55.33% | 19 | Dec 5, 2025 | |
| ALC Alcon | Maintains: Outperform | $95 → $98 | $75.40 | +29.97% | 11 | Nov 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $59.32 | +51.72% | 15 | Sep 26, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $26.49 | -13.17% | 10 | May 27, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $321.43 | +26.00% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $177.28 | +55.69% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $182.87 | +30.15% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $23.40 | +199.15% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.21 | +329.28% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $11.78 | +468.76% | 6 | Feb 18, 2022 |
Henry Schein
Feb 23, 2026
Upgrades: Outperform
Price Target: $78 → $100
Current: $76.12
Upside: +31.37%
Beta Bionics
Feb 18, 2026
Maintains: Neutral
Price Target: $28 → $14
Current: $10.08
Upside: +38.89%
Tandem Diabetes Care
Dec 16, 2025
Upgrades: Outperform
Price Target: $18 → $30
Current: $18.63
Upside: +61.03%
Zimmer Biomet Holdings
Dec 16, 2025
Downgrades: Neutral
Price Target: $117 → $100
Current: $82.80
Upside: +20.77%
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $98
Current: $63.09
Upside: +55.33%
Alcon
Nov 13, 2025
Maintains: Outperform
Price Target: $95 → $98
Current: $75.40
Upside: +29.97%
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $59.32
Upside: +51.72%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $26.49
Upside: -13.17%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $321.43
Upside: +26.00%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $177.28
Upside: +55.69%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $182.87
Upside: +30.15%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $23.40
Upside: +199.15%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.21
Upside: +329.28%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $11.78
Upside: +468.76%